Home » Clinical Trials » Leukemia » NCT06277011
NCT06277011

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Study Summary

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies

Interested in this trial?

Submit an Inquiry

Interventions

Metabolically Armed CD19 CAR-T cellsDRUG
Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.

Study Locations

FacilityCityStateCountry
Anhui Provincial HospitalHefeiAnhuiChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026